Front Row Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Front Row Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-100	Closed	–	–	1036
2020 Q1	$0	Hold	100	–	–	﹤0.01%	1078
2019 Q4	$1K	Hold	100	–	–	﹤0.01%	900
2019 Q3	$1K	Hold	100	–	–	﹤0.01%	905
2019 Q2	$1K	Hold	100	–	–	﹤0.01%	1007
2019 Q1	$0	Buy	+100	New	+$452	﹤0.01%	1117

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Front Row Advisors's PGNX Position: Q2 2020 in Review

Front Row Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 100 shares.

Front Row Advisors first reported a position in PGNX in Q1 2019 and held it in 5 quarters. The position peaked at $1K in Q4 2019. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Front Row Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Front Row Advisors sold 100 Progenics Pharmaceuticals Inc shares in Q2 2020.
Front Row Advisors first reported a position in Progenics Pharmaceuticals Inc in Q1 2019 and held it in 5 quarters.
Front Row Advisors's Progenics Pharmaceuticals Inc position peaked at $1K in Q4 2019.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Front Row Advisors's 13F filing for Q2 2020, filed 17 Aug 2020.